# Article information:

针对SARS-CoV-2和新兴变异株的循环RNA疫苗-PubMed
<https://pubmed.ncbi.nlm.nih.gov/35460644/>

# Article summary:

1. Researchers have developed a circular RNA (circRNA) vaccine that can induce effective neutralizing antibodies and T cell responses against SARS-CoV-2 in mice and rhesus macaques.

2. The circRNA vaccine is more effective than mRNA vaccines, producing higher and more sustained antigen levels, as well as higher proportions of neutralizing antibodies and a significant Th1 bias in the immune response.

3. The circRNA vaccine was found to be effective against the Omega variant but not the Delta variant, while the circRNARBD-Triazole vaccine provided protection against both variants or acted as an enhancer after two doses of natural or Delta-specific vaccines.

# Article rating:

Appears moderately imbalanced: The article provides some useful information, but is missing several important points or pieces of evidence that would be required to present the discussed topics in a balanced and reliable way. You are encouraged to seek a more balanced perspective on the presented issues by exploring the provided research topics and looking at different information sources.

# Article analysis:

This article provides a detailed overview of the development of a circular RNA (circRNA) vaccine for SARS-CoV-2, which has been tested in mice and rhesus macaques with promising results. The authors provide evidence that this vaccine is more effective than mRNA vaccines, producing higher and more sustained antigen levels, as well as higher proportions of neutralizing antibodies and a significant Th1 bias in the immune response. Furthermore, they demonstrate that it is effective against the Omega variant but not the Delta variant, while their circRNARBD-Triazole vaccine provides protection against both variants or acts as an enhancer after two doses of natural or Delta-specific vaccines.

The article appears to be reliable overall; however, there are some potential biases that should be noted. For example, there is no discussion of possible risks associated with this type of vaccine or any potential side effects that may arise from its use. Additionally, there is no mention of any other types of vaccines that may be available for SARS-CoV-2 or how this particular one compares to them in terms of efficacy and safety. Furthermore, there is no exploration into any counterarguments regarding this type of vaccine or any potential drawbacks associated with its use. Finally, it should also be noted that the authors do not present both sides equally; instead they focus solely on promoting their own product without providing any critical analysis or alternative perspectives on its use.

# Topics for further research:

* SARS-CoV-2 vaccine risks
* SARS-CoV-2 vaccine comparison
* CircRNA vaccine side effects
* CircRNA vaccine drawbacks
* SARS-CoV-2 vaccine alternatives
* Critical analysis of circRNA vaccine

# Report location:

<https://www.fullpicture.app/item/d9173ddd34232ee37588d90f0e0cbe5b>